Numinus Wellness Inc. (OTC:LKYSF)(TSXV:NUMI)

First-Mover Licensing Advantage Gives this Company a Leg Up in Potential $2.5 Trillion Mental Health Market

Press Release:

Numinus announces milestones in compassionate access trial for MDMA-assisted therapy in collaboration with MAPS Public Benefit Corporation

Numinus Wellness Inc. (OTC:LKYSF)(TSXV:NUMI) is an integrated mental health company creating an ecosystem of health solutions to research, develop, and deliver safe, evidence-based, accessible psychedelic-assisted psychotherapy. It also appears to be the first public company in Canada to receive a license to produce and extract psilocybin from mushrooms, and to complete the first legal harvest of psilocybin-producing mushrooms in Canada.

  • Numinus Wellness just announced a compassionate access trial of psilocybin-assisted psychotherapy for multiple substance abuse disorders— apparently the first in Canada
  • Numinus Wellness seems to be the first Canadian public company to complete legal harvest of psilocybe mushrooms under its Health Canada-issued Controlled Drugs and Substances Dealer’s License.(A)
  • In clinical studies, psilocybin is proving to be effective in treating mental health issues, such as depression, anxiety, obsessive-compulsive disorder, PTSD, and eating disorders, as well as substance use disorders.(1)
  • Dozens of medical studies from institutions such as Johns Hopkins Medicine and New York University are showing promising results. The US FDA has also shown its support by granting breakthrough therapy status to a host of psychedelic research trials.

Psychedelics could soon revolutionize the $2.5 trillion mental health market.

All with psychedelic drugs like psilocybin.

It’s part of the reason that Eight Capital estimates the total market for mental health treatment could be valued at up to $100 billion.(11)

“In my opinion, psychedelic-assisted psychotherapy smashes the existing mental health treatment paradigm since it does not rely on the use of existing mental health medications, which focus on long term symptom management and often have harmful side effects, and instead approaches the treatment of mental health from the perspective that most common mental health challenges from depression to anxiety can often be cured with psychedelic treatments, whereby individuals no longer meet the symptom requirements. Individuals describe psychedelic assisted psychotherapy as among the most meaningful experiences of their lives, and are often able to reset their lives in a tremendously positive and powerful way. I am personally confident that these treatments will become routine in the health care system in the future and will dramatically improve upon existing approaches.” – Dr. Evan Wood.

Are There Higher Highs Ahead for Psychedelics, like Psilocybin & MDMA?

For one, the US FDA is backing research into psilocybin, through a series of approvals granting “breakthrough therapy” status to psilocybin research efforts in the US.(4)


Numinus Bioscience harvests the first legal flush of Psilocybe mushrooms at its 7000 square foot research and development lab (Numinus Wellness Inc.)

Two, clinical studies from the likes of Johns Hopkins and New York University are already showing positive results, furthering the FDA’s breakthrough therapy status designations. Other studies show similar trends:

  • A study from JAMA Psychiatry just found that psilocybin “worked better than the usual antidepressant medications,” as noted by NPR.(5)
  • Johns Hopkins Medicine launched the Center for Psychedelic and Consciousness Research to study compounds like LSD and psilocybin to treat a range of mental health problems, including anorexia, addiction and depression.(6)
  • A study in the journal, Nature— Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms – showed that 47% of treatment-resistant patients with depression showed positive responses five weeks after psilocybin treatments.(7)

Three: states across the US have initiated promising policy reform that is steadily trending upward. In November alone, Oregon decriminalized all drugs in one measure and legalized psychedelics in another, while Washington DC decriminalized use of natural psychedelics. Meanwhile, the cities of Denver, Oakland and Santa Cruz have also taken similar steps, decriminalizing the possession of personal-use amounts of drugs.(8)

Four, investor attention is rapidly ramping up across North America and Europe

  • Compass Pathways became the first to break into U.S. markets, and has become one of the most valuable psychedelic stocks on the market with a market cap of $1.21 billion.(10)
  • ATAI recently raised $125M, with lead orders from COMPASS backers Peter Thiel and Christian Angermayer
  • MindMed was first to enter the market and now has a market cap of over $600 million backed by former Canopy CEO, Bruce Linton, and Kevin O’Leary of Shark Tank fame.(9)

This combination of robust clinical research and growing investor attention makes a mainstream industry surge only a matter of time, including attention from major pharmaceutical companies—and Numinus is perfectly positioned with its ecosystem lying at the intersection of scientific research, therapy development and therapy delivery.

Numinus Wellness Inc. (OTC:LKYSF)(TSXV:NUMI):

Appears To Be The First Canadian Psychedelics Company to Legally Harvest Magic Mushrooms

Numinus Wellness Inc. (OTC:LKYSF)(TSXV:NUMI) is an integrated mental health company creating an ecosystem of health solutions to research, develop, and deliver safe, evidence-based, accessible psychedelic-assisted psychotherapy.

It seems to be the first public company in Canada to receive a license to produce and extract psilocybin from mushrooms, issued by Health Canada. With that license, Numinus has now completed the first legal harvest of psilocybe mushrooms in Canada by a public company. The license also allows Numinus to test, import, store, and distribute psilocybin and psilocin.

According to the company:

“This first-mover advantage allows us to research and develop proprietary, standardized extraction methods, testing methods and product formulations—for use in R&D partnerships, contract research services, and clinical trials.”

Numinus also possesses a dealer’s license from Health Canada to import, expert, possess, test, and distribute MDMA, psilocybin, psilocin, DMT, and mescaline.

“Numinus is taking crucial step towards establishing healthcare solutions that sustainably treat those with mental illness, and addiction, and towards developing an approach to mental wellbeing that is curative and proactive rather than symptom-treating”, says CEO Payton Nyquvest.

However, That’s Just a Fraction of the Numinus Wellness Growth Story

Other recent developments include:

Numinus Health — Numinus’s existing wellness clinic where psychedelic-assisted psychotherapy will be delivered by industry leading practitioners, once regulated. The site is currently the beta-testing site for psychedelic protocols, while also delivering non-psychedelic services for revenue generation. Upgrades have commenced to retrofit the clinic to specifications set by psychedelic therapy industry leader, the  Multidisciplinary Association of Psychedelics Studies (MAPS), thereby setting a blueprint for Numinus to develop a network of clinics nationally and internationally.

Numinus R&D — Numinus’s medical unit for therapeutic protocol development, in partnership with regulators and leading research institutions. Research is underway to support the company’s stated strategic plan to undertake psilocybin and MDMA clinical research. Numinus recently announced its first clinical trial, for psilocybin-assisted psychotherapy to treat substance use disorders.

Numinus Bioscience — Numinus’s Health Canada-licensed laboratory for psychedelic substance research. It currently holds the company’s first-in-country license by a public company to develop proprietary cultivation and extraction methods for psilocybin from mushrooms, through which it has completed the first mushroom harvest. Other licensing rights include a dealer’s licence to import, export, possess, test, and distribute MDMA, psilocybin, psilocin, DMT, and mescaline; and a cannabis testing licence to provide 3rd-party analytics & testing services for revenue generation. The significant license application processes which Numinus has successfully completed present a high barrier to entry for other market entrants.

“Numinus is setting the stage – and establishing its leadership position – for a future state where psychedelic-assisted psychotherapies are approved for clinical use outside of research,” says Payton Nyquvest, Founder, CEO, and Board Chair. “We are progressing on our mission right now by creating the infrastructure and advancing evidence-based research to support routine clinical use in the health care system. We have the infrastructure, licenses, resources, and expertise to help hasten evidence-based accessibility to these treatments so we can, ultimately, help people heal.”(11)

Numinus Wellness Inc. (OTC:LKYSF)(TSXV:NUMI) Technicals Also Impressive

After pulling back from an approximately $1.01 high close to less than about 20 cents, shares of NUMI pushed back to 80 cents in recent weeks. At the moment, it would appear that investors are just beginning to recognize the value of the company. No doubt this has also been helped by a recent $25M bought deal for the company’s peer, MindMed, which trades at a much higher valuation.

Plus, its short-, medium-, and long-term indicators are all positive, including its 20-day MA, 20-50 day MACD oscillator, 20-100 day MACD oscillator, 20-200 day MACD oscillator, 50-day MA, 50-100 day MACD oscillator, 50-150 day MACD oscillator, 50-200 day MACD oscillator, 100-day MA, 150-day MA, 200-day MA, and its 100-200 day MACD oscillator.

Strong Leadership, Strong Results (OTC:LKYSF)(TSXV:NUMI)

Successful companies tend to possess common traits, and one of those traits is a strong management team.  Numinus Wellness certainly has that ground covered. The company appears to have done a spectacular job of bringing together a leadership team that exists at the intersection of science-based research, policy making, finance, and notable names in the psychedelic space.

Payton Nyquvest, Chairman and CEO

Former Director, VP and Head of Sales at Mackie Research Capital, one of Canada’s largest independent brokerage firms, with a focus on public health and human advancement. Fifteen years’ experience in investment banking, has raised over $100 million for 100+ public and private companies. Former investment advisor with Jordan Capital Markets, Canaccord Financial.

Stacey Wallin, Chief Strategy Officer 

Former founder and CEO of LifeBooster, a tech startup now helping Fortune 100 clients detect and proactively respond to workplace injury risks. She most recently was the Director of Venture Programs at the BC Tech Association, leading the team developing accelerators for scale companies in BC with a mandate of solving the largest ecosystem and policy-related challenges facing growth and scale stage technology companies. Also founded and runs the Canadian Accelerator Incubator Network.

Dr. Evan Wood, MD, PhD, Chief Medical Officer

Recognized researcher with 20+ years of experience in addiction research, most recently as Executive Director of British Columbia Centre on Substance Use (BCCSU). Professor of Medicine at the University of British Columbia. Work on psychedelic-assisted psychotherapy includes involvement with the Multidisciplinary Association for Psychedelics Studies (MAPS) trial of MDMA-assisted psychotherapy and examining the potential of psilocybin assisted psychotherapy for a range of mental health disorders. Dr. Wood was instrumental in the creation of Canada’s supervised injection sites and won in the Supreme Court of Canada to make the program a reality. He was also heavily involved in the creation of international best-practice standards for the HIV/AIDS epidemic and the research that took cannabis into legal status in Canada.

John Fong, Chief Financial Officer 

Experienced financial operator growing technology companies for the past five years, most recently as Managing Director of Invoke Digital. Prior to that, spent 15 years building international financial operations with companies listed on the TSX, NYSE, London AIM, and Lima Stock Exchange, the highlight of which was being on the founding team of Rio Alto Mining, a gold company that in three years went from exploration stage to generating net income of $100 million and operating cash flow of $98 million in its first year of commercial production.

Michael Tan, Chief Operating Officer

Former/first Executive Director, BCLDB Cannabis Division. Successfully launched recreational cannabis operations in BC. Twenty years’ operations management, strategic planning, and execution with national and multinational corporations including Hudson’s Bay, Saks Fifth Avenue, and UPS. Seasoned, high-impact operations, product development, and marketing executive with a track record of driving performance excellence and profitable revenue growth.

Dana Harvey, Chief Communications Officer

Award-winning professional communicator and leader with 25+ years global experience in-house, agency-side, and independent. Honed expertise in strategizing and executing high impact, complex communication requirements for disruptive concepts, emerging industries, and groundbreaking technologies. External communications efforts have resulted in total raises of $60M+, and internal communications leadership has been recognized with multiple awards including the Canadian HR Best Employer Branding Award (2019).

Dr. Devon Christie, MD, CCFP, IFMCP, RTC, Medical Director and Member of Clinical Advisory Council

Family physician with a focused practice in Multidisciplinary Pain Management and Registered Therapeutic Counselor, emphasizing Relational Somatic Therapy for trauma resolution. Teacher in the Certificate in Psychedelic-Assisted Therapies and Research post-graduate program at the California Institute of Integral Studies (CIIS). Trained to deliver MDMA-assisted psychotherapy for PTSD (MAPS USA) and ktamine-assisted psychotherapy. Certified in Functional Medicine, Mindfulness-Based Street Reduction, Interpersonal Mindfulness, and Kundalini Yoga. Recognized speaker and expert on the potential of incorporating psychedelic-assisted therapies in an integrated healthcare model.

Sharan Sidhu, Science Officer and General Manager

Extensive experience as a key strategist for research roadmaps, core initiatives and the development of research requirements and management of research projects and the development of IP. Worked as a hub between academia, industry, and governing directorates to ensure research and development objectives meet regulatory compliance at all phases of pipelines from inception to commercialization. Regulatory expert and policy advisor for restrictive high growth industries. Managed several compliance projects as well as developed requirements for LIMS, GLP, GACP, GMP as well as methods development, vendor qualification, ISO standards and training. Developed several good practices policies and quality management systems and implemented mass change control and overall, all reduction in deviations.

The Top 6 Reasons to Consider Numinus Wellness Inc. (OTC:LKYSF)(TSXV:NUMI)

  1. Numinus’ Leadership and advisory team has a multidisciplinary background with exceptional strength in all the sectors that matter: Science, Policy, Finance, and long-time Psychedelic leaders, and is partnered with industry-leading groups like MAPS and the Heffter Research institute.
  2. Numinus is significantly undervalued when compared to its larger peers, Mindmed and Compass Pathways, and is technically attractive at these prices.
  3. Numinus is currently engaged in trials involving both psilocybin and MDMA, for the treatment of addiction and PTSD, respectively.
  4. Numinus Wellness appears to be the first Canadian public company to complete legal harvest of psilocybe mushrooms under its Health Canada-issued Controlled Drugs and Substances Dealer’s License(A)
  5. Dozens of medical studies from institutions such as Johns Hopkins Medicine and New York University are showing promising results for the treatment of mental health issues like depression, anxiety, obsessive-compulsive disorder, PTSD, and eating disorders.
  6. The US FDA has also shown its support.Psilocybin and MDMA could revolutionize a $2.5 trillion mental health market.

Source A: https://www.newswire.ca/news-releases/numinus-first-canadian-public-company-to-complete-legal-harvest-of-psilocybe-mushrooms-849901430.html

Source 1: https://www.hopkinsmedicine.org/news/newsroom/news-releases/psychedelic-treatment-with-psilocybin-relieves-major-depression-study-shows

Source 2: https://www.nimh.nih.gov/about/directors/thomas-insel/blog/2015/mental-health-awareness-month-by-the-numbers.shtml

Source 3: https://ca.finance.yahoo.com/news/wall-street-eyes-mental-health-as-the-next-great-growth-story-132619645.html

Source 4: https://www.livescience.com/psilocybin-depression-breakthrough-therapy.html

Source 5: https://www.npr.org/sections/health-shots/2020/11/04/931377532/rigorous-study-backs-a-psychedelic-treatment-for-major-depression

Source 6: https://www.nytimes.com/2019/09/04/science/psychedelic-drugs-hopkins-depression.html

Source 7: https://www.nature.com/articles/s41598-017-13282-7

Source 8: https://www.oregonlive.com/politics/2020/11/oregon-becomes-first-state-to-legalize-psychedelic-mushrooms.html

Source 9: https://www.thecannabisinvestor.ca/mindmed-becomes-first-psychedelics-firm-to-go-public-following-historic-ipo/

Source 10: https://observer.com/2020/10/why-magic-mushrooms-are-the-next-big-booming-and-legal-drug-market/

Source 11: https://www.prnewswire.com/news-releases/numinus-commences-psilocybe-mushroom-cultivation-at-its-health-canada-licensed-laboratory-301137266.html

Source 12: https://www.prnewswire.com/news-releases/numinus-commences-psilocybe-mushroom-cultivation-at-its-health-canada-licensed-laboratory-301137266.html

Legal Disclaimer


This website / media webpage is owned, operated and edited by TD Media LLC. Any wording found on this website / media webpage or disclaimer referencing to “I” or “we” or “our” or “TD Media” refers to TD Media LLC. This website / media webpage is a paid advertisement, not a recommendation nor an offer to buy or sell securities. Our business model is to be financially compensated to market and promote small public companies. By reading our website / media webpage you agree to the terms of our disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investing advice or anything of an advisory or consultancy nature and are therefore are unqualified to give investment recommendations. Always do your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis for making investment decisions and is for entertainment purposes only. At most, this communication should serve only as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Conduct your own research. Companies with low price per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service you agree not to hold our site, its editor’s, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our website / media webpage.

We do not advise any reader take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Our website / media webpage are for entertainment purposes only. Never invest purely based on our alerts. Gains mentioned in our website / media webpage may be based on end-of-day or intraday data. This publication and their owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. If we own any shares we will list the information relevant to the stock and number of shares here. TD Media business model is to receive financial compensation to promote public companies. To conduct investor relations advertising, marketing and publicly disseminate information not limited to our Websites, Email, SMS, Push Notifications, Influencers, Social Media Postings, Ticker Tags, Press Releases, Online Interviews, Podcasts, Videos, Audio Ads, Banner Ads, Native Ads, Responsive Ads. This compensation is a major conflict of interest in our ability to be unbiased regarding. Therefore, this communication should be viewed as a commercial advertisement only. We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Any non-compensated alerts are purely for the purpose of expanding our database for the benefit of our future financially compensated investor relations efforts. Frequently companies profiled in our alerts may experience a large increase in volume and share price during the course of investor relations marketing, which may end as soon as the investor relations marketing ceases. Our emails may contain forward-looking statements, which are not guaranteed to materialize due to a variety of factors

We do not guarantee the timeliness, accuracy, or completeness of the information on our website / media webpage. The information in our website / media webpage is believed to be accurate and correct, but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct. Furthermore, TD Media often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are double-checked and verified before publication, but it is certainly possible for errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s). You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. The information in our disclaimers is subject to change at any time without notice.

Pursuant to an agreement between TD Media LLC and Winning Media LLC, TD Media LLC has been hired for a period beginning on 11/30/20 and ending on 12/25/20 to publicly disseminate information about (NUMI) via digital communications. We have been paid fifty thousand USD via bank wire transfer. We own zero shares of (NUMI).

Pursuant to an agreement between TD Media LLC and Winning Media LLC, TD Media LLC has been hired for a period beginning on 12/14/20 and ending on 12/28/20 to publicly disseminate information about (NUMI) via digital communications. We have been paid an additional one hundred thousand USD via bank wire transfer. We own zero shares of (NUMI). To date we have been paid one hundred fifty thousand USD via bank wire transfer. We own zero shares of (NUMI).

Pursuant to an agreement between TD Media LLC and Winning Media LLC, TD Media LLC has been hired for a period beginning on 12/21/20 and ending on 12/28/20 to publicly disseminate information about (NUMI) via digital communications. We have been paid an additional fifty thousand USD via bank wire transfer. We own zero shares of (NUMI). To date we have been paid two hundred thousand USD via bank wire transfer. We own zero shares of (NUMI).

Pursuant to an agreement between TD Media LLC and Winning Media LLC, TD Media LLC has been hired for a period beginning on 12/26/20 and ending on 01/26/21 to publicly disseminate information about (NUMI) via digital communications. We have been paid an additional seventy five thousand USD via bank wire transfer. We own zero shares of (NUMI). To date we have been paid two hundred seventy five thousand USD via bank wire transfer. We own zero shares of (NUMI).

Pursuant to an agreement between TD Media LLC and Winning Media LLC, TD Media LLC has been hired for a period beginning on 1/20/21 and ending on 02/18/21 to publicly disseminate information about (NUMI) via digital communications. We have been paid an additional one hundred thousand USD via bank wire transfer. We own zero shares of (NUMI). To date we have been paid three hundred seventy five thousand USD via bank wire transfer. We own zero shares of (NUMI).

Pursuant to an agreement between TD Media LLC and Winning Media LLC, TD Media LLC has been hired for a period beginning on 02/19/21 and ending on 02/26/21 to publicly disseminate information about (NUMI) via digital communications. We have been paid an additional forty thousand USD via bank wire transfer. We own zero shares of (NUMI). To date we have been paid four hundred fifteen thousand USD via bank wire transfer. We own zero shares of (NUMI).

Pursuant to an agreement between TD Media LLC and Winning Media LLC, TD Media LLC has been hired for a period beginning on 03/1/21 and ending on 03/12/21 to publicly disseminate information about (NUMI) via digital communications. We have been paid an additional forty thousand USD via bank wire transfer. We own zero shares of (NUMI). To date we have been paid four hundred fifty-five thousand USD via bank wire transfer. We own zero shares of (NUMI).